Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
BioViotica
Concanamycin B (high purity)
95
CHF
CHF 95.00
In stock
BVT-0253-C02525 µgCHF 95.00
BVT-0253-C100100 µgCHF 180.00
BVT-0253-C500500 µgCHF 540.00
BVT-0253-M0011 mgCHF 815.00
| Product Details | |
|---|---|
| Synonyms | 8-Deethyl-8-methylconcanamycin A |
| Product Type | Chemical |
| Properties | |
| Formula | C45H73NO14 |
| MW | 852.1 |
| CAS | 81552-33-2 |
| Source/Host Chemicals | Isolated from Streptomyces sp. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, chloroform, acetonitrile or methanol; insoluble in water. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by BioViotica. |
| InChi Key | AQXXGIBOZQZSAT-UZYXLCJWSA-N |
| Smiles | [H][C@@]1(C[C@@H](O)[C@H](OC(N)=O)[C@@H](C)O1)O[C@@H]1C[C@@](O)(O[C@H](\C=C\C)[C@H]1C)[C@@H](C)[C@H](O)[C@H](C)[C@]1([H])OC(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)[C@H](C)CC(C)=C\C=C\[C@@H]1OC |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light when in solution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Antibiotic.
- Exhibits similar activity as concanamycin A (Prod. No. BVT-0237) and concanamycin C (Prod. No. BVT-0254).
- Specific vacuolar-type H+-ATPase inhibitor.
- Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases.
- Suppresses bone resorption.
- Inhibits proliferation of mouse splenic lymphocytes.
- Antifungal and larvicidal.
Product References
- Structures of concanamycins B and C: H. Kinashi, et al.; J. Antibiot. 35, 1618 (1982)
- Isolation and characterization of concanamycins A, B and C: H. Kinashi, et al.; J. Antibiot. (Tokyo) 37, 1333 (1984)
- Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells: M. Yilla, et al.; J. Biol. Chem. 268, 19092 (1993)
- Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosintriphosphatase: S. Drose, et al.; Biochemistry 32, 3902 (1993)
- Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells: F.J. Sharom, et al.; Biochem. J. 308 (Pt2), 381 (1995)
- Concanamycin B inhibits the expression of newly synthesized MHC class II molecules on the cell surface: K. Ito, et al.; J. Antibiot. 48, 488 (1995)
- Concanamycin B, a vacuolar H(+)-ATPase specific inhibitor suppresses bone resorption in vitro: J.T. Woo, et al.; Biol. Pharm. Bull. 19, 297 (1996)
- In vivo rapid reduction of alloantigen-activated CD8+ mature cytotoxic T cells by inhibitors of acidification of intracellular organelles, prodigiosin 25-C and concanamycin B: M. H. Lee, et al.; Immunology 99, 243 (2000)
- Vacuolar H+-ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway: Y. Sasazawa, et. al.; Cancer Sci. 100, 1460 (2009)
- Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins: J. A. Sobota, et. al.; J. Cell Sci. 122, 3542 (2009)
- Inhibitors of V-ATPase: old and new players: M. Huss, et. al.; J. Exp. Biol. 212, 341 (2009)
Related Products
